文献速递神经肿瘤

Marizomib 治疗新诊断胶质母细胞瘤:一项随机 3 期试验

Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial.
PubMed 文献 · Neuro Oncol · 2024-01-01

这项多中心、随机、对照、开放标签 3 期优效性试验纳入 749 例新诊断胶质母细胞瘤患者,比较在标准替莫唑胺放化疗基础上加用 Marizomib 与单用标准治疗。结果显示两组总生存和无进展生存均无显著差异,MGMT 启动子未甲基化亚组亦无差异,但 Marizomib 组 3/4 级治疗中出现的不良事件更多。

要点

  • 标准组与 Marizomib 组中位 OS 为 17 vs 16.5 个月(HR=1.04,P=.64),无显著差异。
  • 两组中位 PFS 为 6.0 vs 6.3 个月(HR=0.97,P=.67),无统计学差异。
  • MGMT 启动子未甲基化患者中位 OS 为 14.5 vs 15.1 个月(HR=1.13,P=.27),无显著差异。

核心结论

  • 在新诊断胶质母细胞瘤患者中,标准替莫唑胺放化疗基础上加用 Marizomib 导致更多毒性,但未改善总生存或无进展生存。

研究设计与样本

  • 欧洲癌症研究与治疗组织 1709/加拿大癌症试验组 CE.8 是一项多中心、随机、对照、开放标签 3 期优效性试验。
  • 关键入选标准包括新诊断胶质母细胞瘤、年龄 > 18 岁、Karnofsky 体能状态 > 70,患者按 1:1 比例随机分组。
  • 试验在欧洲、加拿大和美国的 82 家机构开展,共随机 749 例患者(为计划 750 例的 99.9%)。

主要发现

  • 标准组与 Marizomib 组中位 OS 为 17 vs 16.5 个月(HR=1.04,P=.64),无差异。
  • 标准组与 Marizomib 组中位 PFS 为 6.0 vs 6.3 个月(HR=0.97,P=.67),无统计学差异。
  • MGMT 启动子未甲基化患者中,标准治疗与 Marizomib 组中位 OS 为 14.5 vs 15.1 个月(HR=1.13,P=.27),无差异。
  • Marizomib 组观察到的 CTCAE 3/4 级治疗中出现的不良事件多于标准组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Standard treatment for patients with newly diagnosed glioblastoma includes surgery, radiotherapy (RT), and temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). The proteasome has long been considered a promising therapeutic target because of its role as a central biological hub in tumor cells. Marizomib is a novel pan-proteasome inhibitor that crosses the blood-brain barrier. METHODS: European Organisation for Research and Treatment of Cancer 1709/Canadian Cancer Trials Group CE.8 was a multicenter, randomized, controlled, open-label phase 3 superiority trial. Key eligibility criteria included newly diagnosed glioblastoma, age > 18 years and Karnofsky performance status > 70. Patients were randomized in a 1:1 ratio. The primary objective was to compare overall survival (OS) in patients receiving marizomib in addition to TMZ/RT→TMZ with patients receiving the only standard treatment in the whole population and in the subgroup of patients with MGMT promoter-unmethylated tumors. RESULTS: The trial was opened at 82 institutions in Europe, Canada, and the U.S. A total of 749 patients (99.9% of the planned 750) were randomized. OS was not different between the standard and the marizomib arm (median 17 vs. 16.5 months; HR = 1.04; P = .64). PFS was not statistically different either (median 6.0 vs. 6.3 months; HR = 0.97; P = .67). In patients with MGMT promoter-unmethylated tumors, OS was also not different between standard therapy and marizomib (median 14.5 vs. 15.1 months, HR = 1.13; P = .27). More CTCAE grade 3/4 treatment-emergent adverse events were observed in the marizomib arm than in the standard arm. CONCLUSIONS: Adding marizomib to standard temozolomide-based radiochemotherapy resulted in more toxicity, but did not improve OS or PFS in patients with newly diagnosed glioblastoma.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Roth P, Gorlia T, Reijneveld JC, et al. Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial. Neuro Oncol. 2024. PMID: 38502052. doi:10.1093/neuonc/noae053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。